Randomized phase III trial of consolidation therapy with bortezomib–lenalidomide–Dexamethasone (VRd) vs bortezomib–dexamethasone (Vd) for patients with multiple myeloma who have completed a dexamethasone based induction regimen

Detalles Bibliográficos
Autores principales: Jacobus, S J, Rajkumar, S V, Weiss, M, Stewart, A K, Stadtmauer, E A, Callander, N S, Dreosti, L M, Lacy, M Q, Fonseca, R
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2016
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5030380/
https://www.ncbi.nlm.nih.gov/pubmed/27471864
http://dx.doi.org/10.1038/bcj.2016.55

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5030380/
https://www.ncbi.nlm.nih.gov/pubmed/27471864
http://dx.doi.org/10.1038/bcj.2016.55

Ejemplares similares